VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

Advanced Therapies Week 2022 | Evaluating the development of iSPC-derived MSCs

Tony Ting, PhD, Bone Therapeutics SA, Gosselies, Belgium, provides an overview of the collaboration between Bone Therapeutics and Implant Therapeutics to research the differentiation of induced pluripotent stem cells (iPSCs) into mesenchymal stem cells (MSCs), as well as develop genetically engineered iPSC-derived MSCs. This interview took place at Advanced Therapies Week 2022.

Disclosures

Tony Ting, PhD, is an employee of Bone Therapeutics.